Seoul Pharma Co Ltd

Seoul Pharma Co Ltd has a debt-to-equity ratio of 0.42 and a current ratio of 2.28, indicating a relatively strong liquidity position. The company's free cash flow is 2.52 billion KRW, and its operating cash flow is 1.89 billion KRW, suggesting that it generates sufficient cash to cover its operations and maintain liquidity. The company's profitability is modest, with a return on equity of 1.84% and a return on assets of 1.05%. These figures are below the industry median for pharmaceutical companies, which typically have higher returns due to the high margins associated with drug development and sales. Seoul Pharma Co Ltd's revenue is primarily concentrated in the domestic market, with a significant portion of its sales coming from within South Korea. The company's exposure to overseas markets is limited, which may reduce its growth potential in international markets. The company's growth trajectory is mixed, with a net income of 753.64 million KRW despite an operating loss of 1.28 billion KRW. This suggests that non-operating income or gains may be contributing to profitability. The company's capital expenditure is negative, indicating that it is not investing heavily in new projects or expansion. The risk assessment for Seoul Pharma Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's key financial flag is that its net cash is negative after subtracting total debt, which could pose a challenge if it needs to raise additional capital. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's last actual EPS was 28.00 KRW, which is a key metric for investors to assess its earnings performance.